Sandip K. Agarwala is a Managing Director of Longitude Capital, focused on the identification, evaluation and structuring of investments in the global healthcare sector.
Prior to establishing CrownWheel, Mr. Agarwala was a Vice President with Auven Therapeutics (formerly Celtic Therapeutics), a private equity firm that invests in late development stage biopharmaceutical projects and companies. At Auven, Mr. Agarwala led the evaluation, structuring and management of product acquisitions, private equity, credit and royalty investments across multiple therapeutic areas including oncology, hematology, ophthalmology and rare diseases. Before joining Auven, he was a Consultant in the healthcare practice at the Boston Consulting Group, where he worked with global biopharmaceutical companies on commercial and business development strategies. Mr. Agarwala’s professional experience also includes roles with Healthcare Royalty Partners, Paul Capital Partners, and The Frankel Group, a boutique healthcare consulting firm.
Mr. Agarwala holds an M.B.A. in Finance and Health Care Management from the Wharton School of Business at the University of Pennsylvania, and a B.S.E. in Systems Engineering from the University of Pennsylvania. He has served on the Board of Directors of the Wharton Health Care Management Alumni Association.
Patrick Enright is a founder and Managing Director of Longitude Capital. He focuses on investments in biotechnology.
From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member responsible for the Delta Opportunity Fund, where he invested in privately-held and publicly-traded biotechnology companies. Mr. Enright began his investment career at PaineWebber Development Corporation, a direct investment group focused primarily on biotechnology companies. Mr. Enright also has significant life sciences operations experience including senior executive positions at Valentis, Boehringer Mannheim Pharmaceuticals (now Hoffmann-La Roche) and Sandoz (now Novartis).
He currently serves on the boards of CardioDx, Corcept Therapeutics (NASDAQ: CORT), InfaCare Pharmaceutical Corporation, Jazz Pharmaceuticals (NASDAQ: JAZZ) and Xanodyne Pharmaceuticals. He has previously served on the boards of Codexis (NASDAQ: CDXS), Horizon Pharma (NASDAQ: HZNP), MAP Pharmaceuticals (NASDAQ: MAPP), Prestwick Pharmaceuticals (acquired), Threshold Pharmaceuticals (NASDAQ: THLD) and Sequenom (NASDAQ: SQNM).
Mr. Enright holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.S. in Biological Sciences from Stanford University.
Marc Galletti is a founder and Managing Director of Longitude Capital. He leads Longitude’s proactive research activities that investigates thematic and therapeutic areas of greatest interest for potential investment. Mr. Galletti also leads Longitude’s investor relations activities and focuses on investments in the medical technology and drug delivery sectors. From 2003 to 2006, Mr. Galletti was a Senior Vice President of Pequot Ventures where he worked in the life sciences practice.
Prior to Pequot, Mr. Galletti worked at Amerindo Investment Advisors and Vector Fund Management where prior venture capital investments included Align Technology (NASDAQ: ALGN), CancerVax (acquired by Micromet), Eyetech Pharmaceuticals (NASDAQ: OSIP) and Theravance (NASDAQ: THRX). Mr. Galletti has also worked in the Global Healthcare Investment Banking Group at J.P. Morgan & Co. Mr. Galletti began his life sciences industry career over 15 years ago at APM, a management consultancy dedicated to improving operations performance within large acute-care hospitals.
Mr. Galletti currently serves on the Boards of Aptus Endosystems and Velomedix and he has been involved with prior investments in Ablation Frontiers (acquired), Altiva Corporation (acquired), Facet Solutions (acquired), MAP Pharmaceuticals (acquired), Prestwick Pharmaceuticals (acquired), Sadra Medical (acquired), and Threshold Pharmaceuticals (NASDAQ: THLD).
Mr. Galletti also sits or has sat on advisory boards for the Innovation and New Ventures Office at Northwestern University, the Life Sciences Advisory Board for Silicon Valley Bank, the Program for Biomedical Engineering at Brown University and AdvaMed. Mr. Galletti holds an M.B.A. from the Kellogg School of Management at Northwestern University and an A.B. from Princeton University.
Mr. Diaz is a Venture Partner of Longitude Capital. Concurrent with his position with Longitude Capital, Mr. Diaz is also Managing Director of Auven Therapeutics. Prior to joining Auven Therapeutics, he was a Managing Member and co-founder of Diaz & Altschul Capital Management (D&A Capital). Prior to founding D&A Capital, Mr. Diaz was Managing Director and Head of the Healthcare group at Schroder Wertheim & Co. Mr. Diaz started his career at PaineWebber, where he was a key member of the PaineWebber Healthcare Investment Banking Group and President of PaineWebber Development Corporation. Mr. Diaz holds an M.B.A. from Harvard Business School and a B.A. from Harvard University.
Mr. Abel is an Associate at Longitude Capital. Prior to joining Longitude Capital in 2016, Mr. Abel was an Analyst on the investment team at HealthCare Royalty Partners. Mr. Abel holds a B.S.B.A. in Finance and Healthcare Management from Washington University in St. Louis.